Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “atra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 17
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 17 pipeline programs matching "atra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

17 results for “atra” Back to intelligence hub

Search results

  1. Azacitidine Combined With Venetoclax and ATRA group

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  2. Satralizumab

    Hoffmann-La Roche

    NMDAR Autoimmune Encephalitis

    phase 3 small molecule active

    1 trial
  3. Satralizumab

    Hoffmann-La Roche

    Neuromyelitis Optica (NMO)

    phase 3 small molecule completed

    1 trial
  4. Satralizumab, Satralizumab

    Hoffmann-La Roche

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial
  5. dabigatran

    Yung NA

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial
  6. dabigatran dose 1

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial
  7. dabigatran etexilate

    Boehringer Ingelheim

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial
  8. VESANOID 10 mg, capsule molle

    The George Institute

    Oligometastatic solid cancer

    phase 2 small molecule active

    1 trial
  9. ATRA

    United Therapeutics Europe Ltd

    Pancreatic Adenocarcinoma

    phase 1 small molecule completed

    1 trial
  10. Dabigatran

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 1 small molecule terminated

    1 trial
  11. Dabigatran Etexilate

    CORCEPT THERAPEUTICS INC

    Cushing Syndrome

    phase 1 small molecule completed

    1 trial
  12. Satraplatin in combo with vinorelbine

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial
  13. ATRA+Arsenic

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Promyelocytic Leukemia

    approved small molecule active

    1 trial
  14. Dabigatran Etexilate

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial
  15. Satralizumab 120 mg

    Hoffmann-La Roche

    Neuromyelitis Optica Spectrum Disorder

    approved small molecule terminated

    1 trial
  16. ATRA+Venetoclax+Azacitidine

    The First People's Hospital of Lianyungang

    AML, Adult

    small molecule active

    1 trial
  17. cisatracurium

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    ARDS

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.